Phathom Pharmaceuticals, Inc. announced regulatory updates for its approved products, Voquezna Triple Pak and Voquezna Dual Pak, approved in the U.S. for the treatment of H. pylori infection, and its pending New Drug Application (NDA) for vonoprazan for the treatment of erosive esophagitis
The FDA has approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) from AbbVie, an all-oral, interferon-free...
The FDA granted final approval of a New Drug Application for Kitabis Pak, from PulmoFlow, a co-packaging of generic tobramycin...
A 200-patient Phase II pilot study has begun to examine the efficacy and safety of the Shok-Pak, from InflammaGen Therapeutics,...
AbbVie’s New Drug Application (NDA) has been accepted by the FDA for a once-daily, fixed-dose formulation of the components of...
In consultation with the FDA, the US prescribing information for Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) and...
AbbVie has announced new data from its ongoing Phase IIIb TOPAZ-II study evaluating Viekira Pak (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir...
The FDA has approved a supplemental New Drug Application (sNDA) for the use of Viekira Pak (ombitasvir, paritaprevir, and ritonavir...
Phathom Pharmaceuticals, Inc. announced the FDA approved both Voquezna Triple Pack (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and Voquezna Dual Pack (vonoprazan tablets, amoxicillin capsules), for the treatment of Helicobacter pylori (H. pylori) infection in adults.